| ABSTRACTHepatitis C virus (HCV) infection is a global public health hotspot. The probability of chronic hepatitis C infection is extremely high, and it is easy to complicated with complications such as cirrhosis, which seriously endangers health. In recent years, with the birth and development of direct antiviral drugs (DAAs), it has brought good news for the treatment of chronic hepatitis C (CHC). The current pan genotype direct antiviral drugs are the current development trend of hepatitis C treatment. At present, DAAs currently listed in the world mainly include telaprevir/incivek, boceprevir, daclatasvir, sofosbuvir (SOF) and simeprevir; fixed combination preparations containing two or more target inhibitors are mainly harvoni, epclusa and so on. This article mainly reviews the development of anti viral drugs for hepatitis C and the progress of drug research at home and abroad, in order to provide a basis for the prevention and treatment of hepatitis C in the same industry. |
